Navigation Links
Needle-Free Delivery Devices Shape the Future of Vaccines, Says Frost & Sullivan

LONDON, Sept. 2, 2014 /PRNewswire/ -- Drug delivery technologies that improve access and overall efficacy are becoming an essential part of the entire drug development process. Pharmaceutical companies are particularly investing billions of dollars in new vaccine delivery technologies in a bid to move away from needles and syringes to skin delivery procedures.

New analysis from Frost & Sullivan, Needle-Free Nanopatch Vaccines, finds that though the needle-free delivery sector currently makes up a small fraction of the total drug delivery market, the next five to ten years will see transdermal and intradermal systems (patches and degradable implants), fast-dissolving tablet vaccines, inhalers, and pulmonary delivery methods change the vaccine industry.

While certain forms of needle-free vaccines, such as liquid jet injection, gene guns and micro-needles are already in use, the cell damage caused during administration and the inability to consistently and directly deliver vaccines renders such delivery methods inefficient. Nevertheless, this inefficiency opens doors for vaccine manufacturers to create and commercialise a needle-free system that is not fraught with challenges.

"The delivery of drugs through needle-free devices is gaining acceptance owing to the availability of more formulations for needle-free deliveries," said Frost & Sullivan Healthcare Research Analyst Swathi Allada. "Significant advancements have been made, most of which have centred on addressing patient comfort levels and increasing the adoption of self-injectable therapies."

The development of thermostable vaccines with a long shelf life is another area of focus for many vaccine manufacturers, especially for those marketing to nations where cold-chain storage is an issue. The nanopatch, for instance, eliminates the need for refrigeration as the thermostable vaccine is formulated in dry form, making transportation significantly cheaper than traditional needles.

The nanopatch is a micro-needle patch comprising of little, densely packed micro-projections with a defined geometry. Smaller than a postage stamp – and getting smaller – it is capable of directly depositing vaccine to thousands of skin immune cells without causing damage to the cell membrane in the process.

"The nanopatch achieves precise, controlled and consistent skin penetration along with rapid dissolution and diffusion of the vaccine," noted Allada. "Early stage tests conducted on mouse models have shown that the nanopatch-delivered flu vaccine is effective even with 1/150th of the dose normally given through a traditional syringe."

With successful testing in animals, clinical trials on humans will need to be wrapped up to attain Food and Drug Administration approval. Once this happens, the technology will rapidly gain traction both among patients and physicians, ultimately changing the course of vaccine delivery globally.

For more information on this study, please email Anna Zanchi, Corporate Communications, at

This Market Insight, Needle-Free Nanopatch Vaccines, is part of the Advanced Medical Technologies Growth Partnership Service program. The Insight covers a range of needle-free vaccine deliveries, discussing drivers for adoption and application scope. The study also details the development and potential of the nanopatch as well as its impact on the vaccine industry.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Anna Zanchi
Corporate Communications – Europe
P: +39.02.4851 6133

Logo -

SOURCE Frost & Sullivan
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Needle-Free Delivery: Technology and Market Forecast 2014-2024
2. North American Drug Delivery Technologies Market (Metered Dose Inhalers, Needle-Free Injectors, Auto-Injectors, Nasal Sprays, Transdermal Patches, Nebulizers, Infusion Pumps, Drug Eluting Stents, Sustained Release, Ocular Implants) - Forecasts To 20
3. Increased Dosage of Needle-Free Erectile Dysfunction Medication TriMix-gel Now Available through KRS Global Biotechnology
4. Global Needle-Free Drug Injection Systems and Safety Syringes Industry
5. Global Intranasal Drug Delivery Market 2014-2018: Key Vendors are Becton, Dickinson and Company, GlaxoSmithKline, Johnson & Johnson and Novartis
6. BioDelivery Sciences Announces BEMA Buprenorphine NDA Submission on Track following Pre-NDA Meeting with FDA
7. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of Second Quarter 2014 Financials
8. Global Transdermal Drug Delivery Market 2014-2018: Key Vendors are ANI Pharmaceuticals, Antares Pharma, Bayer, Janssen and Novartis
9. Driven By Product Innovations, the U.S. Drug Delivery Device Market Will Reach Over $4.5 Billion by 2022
10. BioDelivery Sciences Provides Update on Ongoing Phase 3 Pivotal Trial for Clonidine Topical Gel for Painful Diabetic Neuropathy
11. Digital Pathology Market by Slide Scanners, Analytics, Delivery Modes & Whole Slide Image Storage - Global Forecasts & Trends to 2018. In New Research Report Available at
Post Your Comments:
(Date:11/27/2015)... UTRECHT , Niederlande, November 27, 2015 /PRNewswire/ ... mit fotodynamischer Bremachlorin-Therapie bei fortgeschrittenem Krebs.   ... fotodynamischer Bremachlorin-Therapie bei fortgeschrittenem Krebs.   --> ... fotodynamischer Bremachlorin-Therapie bei fortgeschrittenem Krebs.   ... berichtet. --> Clinical Cancer Research ...
(Date:11/26/2015)... Países Bajos, November 26, 2015 ... fotodinámica de Bremachlorin para el cáncer avanzado.   ... con la terapia fotodinámica de Bremachlorin para el cáncer ... enfoque combina la inmunoterapia con la terapia fotodinámica de ... Clinical Cancer Research . --> Clinical Cancer ...
(Date:11/26/2015)... -- Research and Markets ( ) has announced the ... to 2019 - Rise in Cardiac Disorders and Growing Awareness ... their offering. Boston scientific ... scientific and others. --> The market is ... Boston scientific and others. ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... The print ... USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, with a circulation ... is distributed nationally, through a vast social media strategy and across a network ...
(Date:11/27/2015)... ... November 27, 2015 , ... Consistent ... sharing, the 2016 Building Better Radiology Marketing Programs meeting will showcase ... Sunday, March 6, 2016, at Caesars Palace in Las Vegas with a pre-conference ...
(Date:11/27/2015)... ... November 27, 2015 , ... The moment you stop improving ... only fulfilling the needs of advisers and clients but going above and beyond ... top-tier customer service. However, there's always room for improvement, which is why the ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... the largest, most successful and prominent nonprofit healthcare organizations in the country. They ... involvement with various organizations, and helped advance the healthcare industry as a whole ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft ... announces the incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite ... LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk that will receive ...
Breaking Medicine News(10 mins):